Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019943 | 0.92 | TGM2 (0.41) | TGM2DRD4SIGMAR1ACHEHTR6 | |
| SCHEMBL29993724 | 0.92 | TGM2 (0.41) | TGM2DRD4SIGMAR1ACHEHTR6 | |
| SCHEMBL12944880 | 0.92 | TGM2 (0.41) | TGM2DRD4SIGMAR1ACHEHTR6 | |
| SCHEMBL946384 | 0.92 | TGM2 (0.41) | TGM2DRD4SIGMAR1ACHEHTR6 | |
| SCHEMBL5019959 | 0.88 | POLB (0.43) | TGM2DRD4SIGMAR1ACHEHTR6 | |
| SCHEMBL5019961 | 0.85 | XIAP (0.37) | POLBCTSKCTSBCTSSPTGDR2 | |
| SCHEMBL950474 | 0.83 | CTSK (0.35) | TGM2SIGMAR1POLBCTSKCTSB | |
| SCHEMBL19054934 | 0.81 | TGM2 (0.38) | TGM2DRD4SIGMAR1POLBCTSK | |
| SCHEMBL820565 | 0.81 | ERAP2 (0.43) | HTR6GPR84 | |
| SCHEMBL16791288 | 0.80 | TGM2 (0.42) | TGM2DRD4SIGMAR1ACHEHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073579-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130012564-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8283372-B2 | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120115922-A1 | SMAC MIMETEC | MEDIVIR AB (SE) | 2012-05-10 | — | — | US | disclosed |
| US-20110003877-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012564-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885 |
| US-20110003877-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885 |
| US-20120115922-A1 | SMAC MIMETEC | SMARCC1, SMARCC2, SMARCE1 | TGM2 3340/4885DRD4 4877/4885SIGMAR1 2666/4885 |
| US-20140073579-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.